Dendritic cell/tumor fusion vaccine in transplant and CAR-T recipients скачать в хорошем качестве

Dendritic cell/tumor fusion vaccine in transplant and CAR-T recipients

Poorva Bindal, MD, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, explains the rationale for using a dendritic cell/tumor cell fusion vaccine to prevent relapse following allogeneic hematopoietic stem cell transplantation (alloHSCT) or CAR-T therapy. Previous experiments have shown improved outcomes for patients treated with a fusion vaccine. A strategy combining CAR-Ts with the fusion vaccine to induce a potent immune response and activate CAR-Ts is currently being explored. Moving forward, Dr Bindal gives an overview of a Phase I clinical trial evaluating this fusion vaccine in patients with acute myeloid leukemia (AML) who have received alloHSCT (NCT03679650). The study found that patients with lower TGF-β levels had a better response to the vaccine, which led to pre-clinical experiments examinating the impact of a TGF-β inhibitor in combination with the fusion vaccine. In vitro and in vivo are showing enhanced cytotoxicity and decreased levels of immunosuppressive T-cell subsets. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.